Kristin Fiorino
Medical Director AstraZeneca
Seminars
Wednesday 15th April 2026
Enhancing Trial Design Using Pre-clinical & Clinical Insights to Optimize Clinical Endpoints for MASH Drug Development
5:00 pm
- Integrating preclinical and clinical insights to optimize the selection of clinical endpoints, streamlining MASH drug development and accelerating the availability of effective therapies for patients
- Utilizing both preclinical data and clinical evidence to inform clinical trial design, enabling the identification of highly relevant and predictive endpoints that enhance the likelihood of demonstrating drug efficacy and achieving regulatory approval
- Employing preclinical models that accurately mirror MASH pathophysiology, along with clinical insights into disease progression and patient heterogeneity, to focus clinical trials on the most promising therapeutic targets and patient populations— thereby improving the overall success rate of MASH drug development
